Loading...
Dr Muhunthan Thillai & Dr Alessandro Ruggiero
Current
2024
Health Care
Qureight accelerates clinical trial development at key decision points through data curation and AI-powered decision making. They work with pharmaceutical companies, contract research organisations and hospitals to curate data and help the best drugs get approved: so they can be given to patients who need them the most. Qureight are currently focused on lung and heart diseases.
This Cambridge-based business was founded by two highly regarded NHS clinicians turned entrepreneurs, Dr Muhunthan Thillai (CEO) and Dr Alessandro Ruggiero (CSO). Commercial activity began in early 2022 after completing a seed funding round. Since then, the business progressed significantly in revenues and has traction with several large pharma customers, including a three-year strategic partnership with AstraZeneca. Qureight’s solution is highly scalable and has strong potential for global adoption.